{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,2,11]],"date-time":"2025-02-11T05:03:00Z","timestamp":1739250180859,"version":"3.37.0"},"reference-count":23,"publisher":"Oxford University Press (OUP)","issue":"1004","license":[{"start":{"date-parts":[[2009,6,1]],"date-time":"2009-06-01T00:00:00Z","timestamp":1243814400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/pages\/standard-publication-reuse-rights"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2009,6,1]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:p>The prevalence of both osteoporosis and chronic kidney disease (CKD) increases with advancing age. Bisphosphonates are effective in the prevention and treatment of osteoporosis but current recommendations limit their use in patients with renal impairment because of concern regarding the safety profile of these agents in the setting of reduced renal function. The appropriateness of bisphosphonate treatment for patients with CKD is also in question since CKD is independently associated with a variety of skeletal abnormalities, collectively termed renal osteodystrophy, including pre-existing low bone turnover. The evidence to support the current prescribing restrictions is not robust and there are some data to suggest both that bisphosphonate treatment reduces fracture risk without an increase in adverse events in patients with CKD, and that in clinical practice there is underutilisation of this treatment in early CKD. Appropriate prospective trial data with clinically important end points in CKD patients is awaited.<\/jats:p>","DOI":"10.1136\/pgmj.2008.076356","type":"journal-article","created":{"date-parts":[[2009,6,15]],"date-time":"2009-06-15T17:38:07Z","timestamp":1245087487000},"page":"327-330","source":"Crossref","is-referenced-by-count":4,"title":["Chronic kidney disease and bisphosphonate treatment: are prescribing guidelines unnecessarily restrictive?"],"prefix":"10.1093","volume":"85","author":[{"given":"A E","family":"Courtney","sequence":"first","affiliation":[{"name":"Regional Nephrology Unit, Belfast City Hospital , Belfast , UK"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"A P","family":"Maxwell","sequence":"additional","affiliation":[{"name":"Regional Nephrology Unit, Belfast City Hospital , Belfast , UK"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"286","published-online":{"date-parts":[[2009,6,15]]},"reference":[{"author":"National Institute for Health and Clinical Excellence","key":"2023041909285607500_b1","article-title":"Osteoporosis \u2013 secondary prevention"},{"volume-title":"BNF 2008","author":"British National Formulary","key":"2023041909285607500_b2"},{"key":"2023041909285607500_b3","doi-asserted-by":"crossref","first-page":"186","DOI":"10.1111\/j.1525-139X.2007.00271.x","article-title":"Is there a role for bisphosphonates in chronic kidney disease?","volume":"20","author":"Miller","year":"2007","journal-title":"Semin Dial"},{"key":"2023041909285607500_b4","doi-asserted-by":"crossref","first-page":"570","DOI":"10.1007\/s00198-003-1435-y","article-title":"Relationship between age, renal function and bone mineral density in the US population","volume":"14","author":"Klawansky","year":"2003","journal-title":"Osteoporos Int"},{"author":"Medicines Compendium","key":"2023041909285607500_b5"},{"key":"2023041909285607500_b6","first-page":"23","article-title":"Renal transport of bisphosphonates: accumulation by renal cortical slices enhanced by calcium phosphate ions","volume":"106","author":"Troehler","year":"1985","journal-title":"J Lab Clin Med"},{"key":"2023041909285607500_b7","doi-asserted-by":"crossref","first-page":"1164","DOI":"10.1681\/ASN.V1261164","article-title":"Collapsing focal segmental glomerulosclerosis following treatment with high-dose pamidronate","volume":"12","author":"Markowitz","year":"2001","journal-title":"J Am Soc Nephrol"},{"key":"2023041909285607500_b8","doi-asserted-by":"crossref","first-page":"1676","DOI":"10.1056\/NEJM200310233491721","article-title":"Renal failure with the use of zoledronic acid","volume":"349","author":"Chang","year":"2003","journal-title":"N Engl J Med"},{"key":"2023041909285607500_b9","doi-asserted-by":"crossref","first-page":"281","DOI":"10.1046\/j.1523-1755.2003.00071.x","article-title":"Toxic acute tubular necrosis following treatment with zoledronate (Zometa)","volume":"64","author":"Markowitz","year":"2003","journal-title":"Kidney Int"},{"key":"2023041909285607500_b10","doi-asserted-by":"crossref","first-page":"551","DOI":"10.2165\/00003088-200544060-00001","article-title":"Pharmacokinetics\/pharmacodynamics of bisphosphonates: use for optimisation of intermittent therapy for osteoporosis","volume":"44","author":"Cremers","year":"2005","journal-title":"Clin Pharmacokinet"},{"key":"2023041909285607500_b11","doi-asserted-by":"crossref","first-page":"166","DOI":"10.1056\/NEJM199507203330307","article-title":"Renal osteodystrophy","volume":"333","author":"Hruska","year":"1995","journal-title":"N Engl J Med"},{"key":"2023041909285607500_b12","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1007\/s11926-005-0009-8","article-title":"Treatment of metabolic bone disease in patients with chronic renal disease: a perspective for rheumatologists","volume":"7","author":"Miller","year":"2005","journal-title":"Curr Rheumatol Rep"},{"key":"2023041909285607500_b13","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1177\/1478271520093901007","article-title":"Bisphosphonate prescribing in chronic kidney disease","volume":"39","author":"Courtney","year":"2009","journal-title":"J R Coll Physicians Edinb"},{"key":"2023041909285607500_b14","doi-asserted-by":"crossref","first-page":"2105","DOI":"10.1359\/JBMR.050817","article-title":"Safety and efficacy of risedronate in patients with age-related reduced renal function as estimated by the Cockcroft and Gault method: a pooled analysis of nine clinical trials","volume":"20","author":"Miller","year":"2005","journal-title":"J Bone Miner Res"},{"key":"2023041909285607500_b15","doi-asserted-by":"crossref","first-page":"1385","DOI":"10.1038\/ki.2008.356","article-title":"Bisphosphonate nephrotoxicity","volume":"74","author":"Perazella","year":"2008","journal-title":"Kidney Int"},{"key":"2023041909285607500_b16","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1007\/s11914-005-0021-y","article-title":"Treatment of osteoporosis in chronic kidney disease and end-stage renal disease","volume":"3","author":"Miller","year":"2005","journal-title":"Curr Osteoporos Rep"},{"key":"2023041909285607500_b17","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1046\/j.1365-2125.2000.00135.x","article-title":"Effect of renal function on risedronate pharmacokinetics after a single oral dose","volume":"49","author":"Mitchell","year":"2000","journal-title":"Br J Clin Pharmacol"},{"key":"2023041909285607500_b18","doi-asserted-by":"crossref","first-page":"461","DOI":"10.7326\/0003-4819-130-6-199903160-00002","article-title":"A more accurate method to estimate glomerular filtration rate from serum creatinine: a new prediction equation. Modification of Diet in Renal Disease Study Group","volume":"130","author":"Levey","year":"1999","journal-title":"Ann Intern Med"},{"key":"2023041909285607500_b19","doi-asserted-by":"crossref","first-page":"2473","DOI":"10.1056\/NEJMra054415","article-title":"Assessing kidney function\u2014measured and estimated glomerular filtration rate","volume":"354","author":"Stevens","year":"2006","journal-title":"N Engl J Med"},{"key":"2023041909285607500_b20","doi-asserted-by":"crossref","first-page":"566","DOI":"10.1053\/j.ajkd.2003.12.004","article-title":"Osteoporosis in chronic kidney disease","volume":"43","author":"Cunningham","year":"2004","journal-title":"Am J Kidney Dis"},{"issue":"(Suppl 3)","key":"2023041909285607500_b21","first-page":"S1","article-title":"NKF-K\/DOQI Clinical Practice Guidelines","volume":"42","author":"Anon","year":"2003","journal-title":"Am J Kidney Dis"},{"key":"2023041909285607500_b22","doi-asserted-by":"crossref","first-page":"2141","DOI":"10.1046\/j.1523-1755.1999.00461.x","article-title":"Circulating biochemical markers of bone remodeling in uremic patients","volume":"55","author":"Urena","year":"1999","journal-title":"Kidney Int"},{"key":"2023041909285607500_b23","doi-asserted-by":"crossref","first-page":"558","DOI":"10.1053\/j.ajkd.2003.12.003","article-title":"Diagnosis, assessment, and treatment of bone turnover abnormalities in renal osteodystrophy","volume":"43","author":"Martin","year":"2004","journal-title":"Am J Kidney Dis"}],"container-title":["Postgraduate Medical Journal"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/pmj\/article-pdf\/85\/1004\/327\/50020215\/postgradmedj-85-327.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/pmj\/article-pdf\/85\/1004\/327\/50020215\/postgradmedj-85-327.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,2,10]],"date-time":"2025-02-10T04:37:43Z","timestamp":1739162263000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/pmj\/article\/85\/1004\/327\/7007426"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2009,6,1]]},"references-count":23,"journal-issue":{"issue":"1004","published-online":{"date-parts":[[2009,6,15]]},"published-print":{"date-parts":[[2009,6,1]]}},"URL":"https:\/\/doi.org\/10.1136\/pgmj.2008.076356","relation":{},"ISSN":["0032-5473","1469-0756"],"issn-type":[{"type":"print","value":"0032-5473"},{"type":"electronic","value":"1469-0756"}],"subject":[],"published-other":{"date-parts":[[2009,6]]},"published":{"date-parts":[[2009,6,1]]}}}